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SV40-transformed mKSA cells (H-2d) readily induce progressively growing tumors in adult syngeneic BALB/c mice while
expressing the full complement of H-2d MHC class I antigens. BALB/c mice previously immunized with SV40, soluble SV40
T antigen, or irradiated SV40-transformed syngeneic, allogeneic, or xenogeneic cells reject an mKSA tumor challenge even
though these mice have been considered low- or nonresponders to T antigen due to difficulty in demonstrating SV40 T
antigen-specific CTL. We have investigated the role of H-2d-restricted CTL in the rejection of SV40 tumors in BALB/c mice.
Immunization of BALB/c mice with SV40 induced T antigen-specific CTL which were largely H-2Ld-restricted. However,
following repeated in vitro restimulation with mKSA cells, CTL emerged which recognized a subdominant H-2Kd-restricted
epitope corresponding to T antigen residues 499–507. Immunization of BALB/c mice with a recombinant vaccinia virus
expressing the T499–507 epitope provided partial protection against a challenge of syngeneic mKSA tumor cells and induced
the generation of T499–507-specific CTL. These results indicate that a subdominant H-2K
d-restricted CTL epitope can
participate in the rejection of SV40 tumors in BALB/c mice. © 1998 Academic Press
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INTRODUCTION
The DNA tumor virus, simian virus 40 (SV40), encodes
a multifunctional 94-kDa nuclear oncoprotein, the large
tumor or T antigen (SV40 Tag). SV40 Tag initiates and
maintains transformation of a wide variety of cell types in
vitro (Livingston and Bradley, 1987; Levine, 1989; Fan-
ning, 1992). In vivo, Tag can induce neoplasia with a
metastatic potential when expressed as a transgene
under the control of a tissue-specific promoter, or when
expressed from the viral promoter (Brinster et al., 1984;
Hanahan, 1985; Palmiter et al., 1985; Ornitz et al., 1987;
Knowles et al., 1990).
SV40 T antigen induces a vigorous cellular immune
response in the immunocompetent host which leads to
rejection of developing, T antigen-induced tumors (re-
viewed in Tevethia, 1980, 1990). Long-term persistence of
SV40 genomes and development of SV40-induced tu-
mors appears to be controlled by MHC haplotype and
correlates inversely with the ability to induce Tag-spe-
cific CTL (Abramczuk et al., 1984; Pan et al., 1987). More-
over, in responder mice, progression of Tag-induced tu-
mors has been correlated with selective loss of the MHC
class I antigen which acts as the restriction element for
Tag-specific CTL induced in that haplotype (Gooding,
1982; Flyer et al., 1983; Pan et al., 1987). Such studies
have characterized mice of the H-2d haplotype as low
responders to Tag and susceptible to SV40-induced tu-
morigenesis (Gooding, 1982; Flyer et al., 1983; Pan et al.,
1987).
BALB/c mice (H-2d) have been termed nonresponders
to SV40 Tag, due to inefficient induction of SV40 Tag-
specific CTL following challenge with SV40-transformed
cells or SV40 (Trinchieri et al., 1976; Pfizenmaier et al.,
1978; Gooding, 1979; Knowles et al., 1979; Pfizenmaier et
al., 1980). BALB/c mice develop progressively growing
subcutaneous tumors when challenged with tumori-
genic, T antigen-transformed cell lines, such as mKSA
(Kit et al., 1969; Zarling and Tevethia, 1973a; Tevethia and
McMillan, 1974), but can reject such tumors if they have
been previously immunized with attenuated (irradiated)
tumor cells, SV40-transformed allogeneic and xenoge-
neic cells, SV40 virus, SV40 Tag-expressing adenovirus
vectors, purified T antigen protein, or plasmid DNA en-
coding SV40 Tag (Zarling and Tevethia, 1973a,b; Law et
al., 1977; Jay et al., 1978, 1979; Tevethia, 1980; Tevethia et
al., 1980; Shearer et al., 1993; Bright et al., 1996; Schirm-
beck et al., 1996). T lymphocytes have long been impli-
cated in the rejection of SV40 T antigen-induced tumors
in BALB/c mice (Tevethia et al., 1974b). From earlier
studies, however, it was unclear whether T lymphocytes
served only to initiate tumor rejection, or provided both
initiation and effector functions (Zarling and Tevethia,
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1973b; Tevethia et al., 1974b, 1977). More recent studies
have demonstrated that SV40 Tag-specific CTL can be
induced by immunization in BALB/c mice with plasmid
DNA encoding SV40 Tag or purified SV40 Tag protein
fragments (Bright et al., 1996; Schirmbeck et al., 1996;
Zerrahn et al., 1996). SV40 Tag-specific CD81 CTL have
been demonstrated in lymphocyte populations purified
from exudates surrounding Tag-induced transplanted tu-
mors in BALB/c mice (Zerrahn et al., 1996). Depletion
studies have provided evidence for the importance of
CD81 CTL in the rejection of SV40 Tag-induced tumors
from BALB/c mice previously immunized against SV40
Tag (Schirmbeck et al., 1996; Zerrahn et al., 1996).
To investigate the role of defined SV40 Tag CTL
epitopes in the rejection of SV40 Tag-induced tumors in
BALB/c mice, we have sought to identify epitopes rec-
ognized by Tag-specific CTL induced following immuni-
zation of BALB/c mice with SV40. We find that im-
munization of BALB/c mice with SV40 induced T anti-
gen-specific CTL, which were predominantly H-2Ld-
restricted. However, following repeated in vitro restimu-
lation, H-2Kd-restricted T antigen-specific CTL emerged.
SV40 Tag-specific H-2Kd-restricted CTL clones recog-
nized an epitope which was mapped to SV40 T antigen
residues 499–507. CTL specific for the T499–507 determi-
nant induced rejection of Tag-induced tumors in vivo.
RESULTS
Induction of SV40 T antigen-specific cytotoxic T
lymphocytes by immunization with SV40
In order to elucidate the role of CD81 H-2d-restricted
CTL in the rejection of SV40-induced (mKSA) tumors, CTL
were generated by immunizing groups of BALB/c mice
twice with SV40. The mice were subsequently chal-
lenged with a lethal dose (1 3 105) of tumorigenic mKSA
cells. SV40-immunized mice rejected an mKSA tumor
challenge, whereas control mice challenged with the
same dose of tumor cells developed progressively grow-
ing tumors (data not shown; Zarling and Tevethia, 1973a).
Splenic lymphocytes were prepared from mice which
had rejected the mKSA tumor cell challenge, and were
restimulated in vitro for 6 days with irradiated mKSA
cells. The results presented in Fig. 1 show that the CTL
generated efficiently lysed SV40-transformed H-2d cells
(mKSA, VLM, BALB/c-pPVU0; see Table 1a), but did not
lyse Tag-transformed H-2b cells (B6/WT19). Efficient lysis
of the Tag-transformed K5RSV cells (Kb, Dd, Ld) but not
Tag-transformed KHTGSV cells (Kd, Db) indicated that the
Tag-specific CTL were restricted by H-2Ld and/or H-2Dd.
Recombinant vaccinia viruses (see Table 1b) were
used to further characterize CTL induced by SV40 in
BALB/c mice (Table 2). Specificity for SV40 Tag determi-
nants was indicated by efficient lysis of P815 cells in-
fected with a vaccinia recombinant which directed ex-
pression of the full-length SV40 Tag (rVV-941T; Fu et al.,
1998). As a control, P815 cells infected with a vaccinia
recombinant which expressed a minigene correspond-
ing to SV40 Tag CTL epitope I (rVV-ES-I; Fu et al., 1998),
an immunodominant H-2Db-restricted epitope corre-
sponding to Tag residues 206–215 (Lippolis et al., 1995),
were not lysed by the same CTL. Similar results were
obtained using splenocytes prepared from mice which
had been immunized 2 weeks previously with a single
injection of 1.5 3 108 plaque-forming units (PFU) of SV40
(Table 2).
To determine whether H-2Ld-restricted Tag-specific
CTL were induced by immunization of BALB/c mice with
SV40, T.1.1.1. cells which express a transfected H-2Ld
gene were infected with either the rVV-941T (full-length T
antigen) or the control rVV-ES-I (T206-215) and used as
targets in the cytotoxicity assay. T.1.1.1. cells infected with
rVV-941T, but not with rVV-ES-I, were efficiently lysed by
CTL derived from both groups of immunized mice (Table
2). These results suggest that at least a portion of
the SV40 Tag-specific CTL were H-2Ld-restricted, and
further demonstrate that a single subcutaneous immuni-
zation of BALB/c mice with SV40 was sufficient to induce
the generation of H-2Ld-restricted SV40 T antigen-spe-
cific CTL.
Emergence of SV40 T antigen-specific, H-2Kd-
restricted CTL
To further characterize the specificity of CTL induced
by immunization of BALB/c mice with SV40, CTL derived
from SV40-immunized mice that had rejected an mKSA
tumor challenge were subcultured in vitro in the pres-
ence of gamma-irradiated mKSA tumor cells. Duplicate
FIG. 1. Recognition of SV40 Tag-transformed cells by bulk-culture
CTL derived from BALB/c mice immunized with SV40. BALB/c mice
were immunized twice with 1.5 3 108 PFU SV40 and subsequently
rejected a lethal mKSA challenge. Splenocytes were harvested after 5
months and restimulated in the presence of irradiated mKSA cells.
Tag-transformed cell lines were tested for lysis by bulk-culture CTL at
the effector-to-target ratios indicated in the figure. Cell lines are de-
scribed in Table 1.
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subcultures were prepared where one set received hu-
man recombinant IL-2, while the other set received Rat
T-Stim culture supplement. Both subcultures were re-
stimulated twice weekly with irradiated mKSA cells and
tested weekly for SV40 Tag-specific CTL activity (data not
shown). The CTL lines established by this procedure
were designated as SVCTL-A (received human recombi-
nant IL-2) and SVCTL-B (received T-Stim culture supple-
ment). The results of several cytotoxicity assays revealed
that SV40 T antigen-specific, H-2Ld-restricted CTL ex-
panded readily and were maintained for at least several
weeks under both sets of culture conditions (data not
shown).
The results of a cytotoxicity assay performed follow-
ing seven in vitro restimulations of the SVCTL-A and
SVCTL-B cultures are presented in Table 3. These
results illustrate that, at that stage, both the SVCTL-A
and SVCTL-B CTL lines specifically lysed mKSA and
BALB/c-pPVU0 (H-2d, Tag1) targets. Efficient lysis of
Tag-transformed K5RSV cells, which express H-2Dd
and H-2Ld, but not H-2Kd MHC Class I antigens
(Knowles et al., 1979) implied that H-2Ld- and/or
H-2Dd-restricted Tag-specific CTL were present in
both the SVCTL-A and SVCTL-B cultures. Tag-trans-
formed KHTGSV cells which do not express H-2Dd or
H-2Ld class I molecules, but do express H-2Kd mole-
cules (Knowles et al., 1979), were not lysed by the
SVCTL-A CTL. By contrast, the SVCTL-B CTL did lyse
the KHTGSV cells (Table 3). The lysis of the KHTGSV
cells by the SVCTL-B CTL was weaker when compared
to lysis of the K5RSV cells by either CTL line (Table 3).
These results suggested that a mixture of H-2Kd- and
H-2Ld-restricted SV40 Tag-specific CTL were present
in the SVCTL-B line. Following continued in vitro sub-
TABLE 1a
Cell Lines Used in This Study
Cell line
Transforming
Agent
Tag
expression
Haplotype
ReferenceK D L
mKSA SV40 Yes d d d Kit et al., 1969
VLM SV40 Yes d d d Tevethia and McMillan, 1974
BALB/c-pPVU0 pPVU0 Yes d d d This study
P815 Methcholanthrene No d d d Dunn and Potter, 1957
B6/WT19 SV40 Yes b b — Tevethia et al., 1979
T.1.1.1. — No k k d Marguiles et al., 1983
K5RSV SV40 Yes b d d Knowles et al., 1979
KHTGSV SV40 Yes d b — Knowles et al., 1979
L/Kd — No k,d k — Eisenlohr et al., 1992
BALB/c/SVT-1B3 pSelectESV Yes d d d This study
BALB/c/TD499–507-3B2 pTD499–507 Yes d d d This study
(T; D499–507)a
BALB/c/TY500A-5A2 pTY500A Yes d d d This study
(T; Y500A)
a Indicates deletion mutation or single residue substitution in SV40 Tag encoded by the transforming plasmid DNA.
TABLE 1b
Recombinant Vaccinia Viruses Used in This Study
Vaccinia recombinant Inserta Reference
rVV-SC None Fu et al., 1998
rVV-941T SV40 T antigen-encoding cDNA Fu et al., 1998
rVV-ES-I (or ES-T206-215) ES-SAINNYAQKLb Fu et al., 1998
rVV-ES-T499–507 ES-DYLDGSVKVb This study
rVV-Kd H-2Kd-encoding cDNA Restifo et al., 1993
rVV-Ld H-2Ld-encoding cDNA
Yewdell et al.,
1993
rVV-Dd H-2Dd-encoding cDNA
Yewdell et al.,
1993
a All recombinants were constructed by recombination of inserts into the vaccinia strain WR by using a derivative of the vector pSC11.
b These recombinants encode a 16 residue ES leader sequence and an additional Ala residue (RYMILGLLALAAVCSAA) fused to the amino terminus
of sequences encoding the indicated epitope peptides.
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culture, the results of cytotoxicity assays indicated that
H-2Kd-restricted, Tag-specific CTL eventually predom-
inated within the SVCTL-B line (data not shown).
Similar results were obtained following repeated in
vitro restimulation of splenocytes obtained from groups
of BALB/c mice immunized with SV40 alone (data not
shown). Thus, repeated restimulation in vitro in the pres-
ence of different sources of cytokines resulted in the
preferential expansion (and maintenance) of H-2Ld- and
H-2Kd-restricted, SV40 T antigen-specific CTL from bulk-
cultured CTL derived from BALB/c mice immunized with
SV40, whether or not the mice had received a subse-
quent mKSA challenge. The mechanisms which lead to
the outgrowth of Tag-specific CTL which differ in speci-
ficity and restriction depending upon the cytokine source
remain unknown.
Mapping of an H-2Kd-restricted CTL epitope within
SV40 T antigen
In order to map the recognition epitopes of the BALB/
c-derived T antigen-specific CTL, CTL clones were es-
tablished from both the SVCTL-A and SVCTL-B pools by
limiting dilution. SV40 Tag-specific CTL clones derived
from the SVCTL-A pool (and a second SVCTL-A-like pool
generated independently from SV40-immunized mice)
were H-2Ld-restricted, while clones derived from the
SVCTL-B pool were H-2Kd-restricted (data not shown;
see below). Five CTL clones from each pool were ex-
panded for further analysis. The CTL clones were shown
to be CD81, ab TCR1 and CD42, gd TCR2 by flow
cytometry (data not shown). We were unable to map the
SV40 Tag epitope(s) recognized by the H-2Ld-restricted
CTL clones.
TABLE 2
SV40 T Antigen-Specific Cytotoxic T Lymphocytes Induced by Subcutaneous Immunization with SV40
Effectors from
BALB/c mice
immunized with: E:T
Percentage specific target cell lysis
BALB/c-
pPVU0
(T1, H-2d)
P815 (H-2d) T.1.1.1. (H-2k/Ld)
None
1rV V-a 1 rV V-
941T ES-I 941T ES-I
SV40 3 mKSAb 50:1 52 8 73 12 48 7
17:1 35 4 58 5 28 2
6:1 17 2 35 2 13 1
SV40c 50:1 50 8 62 7 40 8
17:1 34 4 45 3 19 2
6:1 17 2 21 2 8 0
a Target cells were infected with the indicated rVVs at an m.o.i. of 10 for 6 h, washed, and mixed with effectors in a 5-h 51Cr release assay at the
indicated effector-to-target ratios.
b Mice were immunized twice subcutaneously with 1.5 3 108 PFU SV40 and rejected an mKSA tumor challenge. Splenocytes were prepared 9
months after tumor challenge and restimulated in vitro with mKSA cells.
c Mice were immunized subcutaneously with 1.5 3 108 PFU SV40, and splenocytes were prepared 2 weeks later.
TABLE 3
Expansion of SV40 T Antigen-Specific H-2Ld- and H-2Kd-Restricted CTL Lines in Vitro
Effector
CTL lineb E:T
Percentage specific lysis of target cells
mKSA
(T1)a
(H-2d)
BALB/c pPVU0
(T1) (H-2d)
K5RSV
(T1)
(Kb/Dd/Ld)
KHTGSV
(T1)
(Kd/Db)
P815
(T2)
(H-2d)
B6/WT19
(T1)
(H-2b)
SVCTL-A 10:1 95 84 67 6 34 14
3:1 91 72 51 2 19 6
1:1 74 47 29 1 9 0
SVCTL-B 10:1 90 84 65 35 15 15
3:1 83 75 44 28 8 8
1:1 65 54 21 15 2 3
a T1, SV40 Tag-transformed cell line.
b CTL lines derived from SV40-immunized BALB/c mice were used in this experiment at passage 7 in vitro.
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To define a region of T antigen which contained an
H-2Kd-restricted determinant, we initially took advantage
of existing pools of synthetic, overlapping 15 and 18-mer
peptides which corresponded to SV40 Tag sequences
spanning residues 364–516. These pools were used to
pulse P815 cells for use in lysis assays employing the
SV40 Tag-specific H-2Kd- and H-2Ld-restricted CTL
clones. The results of those assays suggested that pep-
tides spanning Tag residues 489–516 contained a deter-
minant recognized by the H-2Kd-restricted CTL clones,
while the H-2Ld-restricted CTL clones and bulk-cultured
splenocytes from SV40-immunized BALB/c mice failed to
recognize determinants in the same pools (data not
shown). Results obtained using peptides corresponding
to T antigen sequences 489–503 (SV26), 494–508 (SV27),
and 499–516 (SV28; Fig. 2A) showed that the H-2Kd-
restricted CTL clone 19A8 efficiently lysed P815 cells
pulsed with the peptide SV28 (Fig. 2B).
The 9-mer sequence corresponding to residues 499–
507 of SV40 Tag, DYLDGSVKV, shares similarity with
H-2Kd-binding peptides (Fig. 2A) which are often 9-mers
that contain a Tyr or Phe residue at Position 2 and an Ile,
Leu, or Val at Position 9 (Rammensee et al., 1993). A
9-mer peptide, LT499–507, was synthesized and used to
sensitize P815 cells for lysis by the SV40 Tag-specific,
H-2Kd-restricted CTL clones. The results of a represen-
tative experiment using CTL clone 19A8 presented in Fig.
2C show that this clone specifically lysed P815 cells
FIG. 2. Recognition of peptide-pulsed targets by the SV40 T antigen-specific, H-2Kd-restricted CTL clone 19A8. (A) Amino acid sequences of peptides
SV26, SV27, and SV28. The predicted H-2Kd-binding motif is underlined. (B) SV40 T antigen-specific, H-2Kd-restricted CTL clone 19A8 was tested for
reactivity against P815 cells pulsed with synthetic peptides corresponding to T antigen amino acid sequences in a standard cytotoxicity assay. Peptide
SV26 was used at 37.5 mM, peptide SV27 was used at 30 mM, and SV28 was used at 26 mM. (C) CTL clone 19A8 was tested at an effector-to-target
ratio of 10:1 for reactivity against P815 cells pulsed with decreasing concentrations of the synthetic 9-mer peptide LT499–507 (DYLDGSVKV).
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pulsed with the LT499–507 peptide at concentrations
ranging from 1 mM to 1 nM. Similar results were obtained
for each of the five CTL clones tested. We speculate that
recognition of peptide SV27 may have been impaired by
the single Asn residue extension carboxyterminal to the
9-mer DYLDGSVKV sequence (Sherman et al., 1992).
To confirm that the sequence DYLDGSVKV within Tag
was important for recognition of Tag-transformed cells by
the H-2Kd-restricted CTL clones, derivatives of SV40 Tag
were generated by site-directed mutagenesis from which
either sequences encoding the 9-mer DYLDGSVKV were
deleted, or in which the codon specifying Y500 was
substituted with an alanine codon. Transformed cell lines
were derived from BALB/c kidney cells following trans-
fection with these Tag derivatives and were assayed for
lysis by the SV40-specific H-2Kd-restricted CTL clones.
The results of lysis assays (Fig. 3) confirmed that efficient
lysis of Tag-transformed H-2d cells required the pres-
ence of Tag residues 499–507. Moreover, the Y500A
substitution abolished recognition (Fig. 3), supporting a
key role for this H-2Kd anchor residue in recognition by
the SV40-specific H-2Kd-restricted CTL clones.
Expression of the H-2Kd-restricted Tag epitope
(T499–507) as minigene in a recombinant
vaccinia virus
To examine the presentation and immunogenicity of
the sequence DYLDGSVKV, a recombinant vaccinia virus
(rVV-) was constructed which encoded the H-2Kd-re-
stricted CTL epitope, T499–507, as a minigene linked to an
endoplasmic reticulum insertion signal sequence (ES)
derived from the adenovirus glycoprotein E3/19K (Eisen-
lohr et al., 1992; Bacik et al., 1994). P815 cells infected
with the rVV-ES-T499–507 recombinant were efficiently
lysed by the T antigen-specific H-2Kd-restricted CTL
clones (Fig. 4). Uninfected P815 cells (Fig. 4e) or P815
cells infected with a control vaccinia recombinant (rVV-
ES-I; Fig. 4b) were not lysed by these CTL clones. As
expected, P815 cells sensitized with the synthetic pep-
tide LT499–507 were recognized by each of the H-2Kd-
restricted CTL clones (Fig. 4d). Taken together, our re-
sults suggest that the peptide sequence DYLDGSVKV
FIG. 3. Residues 499–507 are required for recognition of Tag-trans-
formed H-2d cells by CTL clone 19A8. Tag-transformed cell lines were
tested for lysis by CTL clone 19A8 at the effector-to-target ratios
indicated in the figure. Cell lines are described in Table 1.
FIG. 4. A vaccinia recombinant bearing an ES-linked minigene encoding Tag residues 499–507 sensitizes target cells to lysis by SV40 T
antigen-specific H-2Kd-restricted CTL clones. P815 cells (e), or P815 cells infected with vaccinia recombinants [(a) rVV-ES-T499–507; (b) rVV-ES-T206-
215; (c) rVV-941T] at an m.o.i. of 10 for 6 h or pulsed with the synthetic peptide LT499–507 (d) for 1 h at a concentration of 1 mM were tested for lysis
by SV40 T antigen-specific, H-2Kd-restricted CTL clones at the indicated effector-to-target ratios.
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represents a minimal epitope which can be processed
and presented from T antigen-transformed cells, and is
recognized by the H-2Kd-restricted, SV40 Tag-specific
CTL clones. However, the H-2Kd-restricted CTL clones
failed to lyse P815 cells infected with the rVV-941T which
drives synthesis of full-length Tag (Fig. 4c; see below).
The source of SV40 Tag determinants controls the
efficiency of target cell recognition by SV40 T
antigen-specific H-2Ld- and H-2Kd-restricted CTL
clones
Both the H-2Kd- and the H-2Ld-restricted CTL lines and
CTL clones were specific for SV40 Tag, but efficient
recognition by the CTL clones differed markedly depend-
ing on whether the source of T antigen was endogenous
(Tag-transformed cells) or generated by infection with
rVV-941T. The results of a representative cytotoxicity ex-
periment employing the CTL clones 19A8 (H-2Kd-re-
stricted) and 1H7 (H-2Ld-restricted) are presented in Ta-
ble 4. The H-2Kd-restricted Tag-specific CTL clone 19A8
(and all other H-2Kd-restricted clones tested) specifically
lysed Tag-transformed H-2d cell lines such as mKSA and
BALB/c-pPVU0 (Table 4). The clone 19A8 also specifi-
cally lysed Tag-transformed B6/WT19 cells (H-2b) follow-
ing infection with rVV-Kd. The specificity of the 19A8
clone for the DYLDGSVKV (T499–507) determinant and its
H-2Kd-restriction are illustrated by specific lysis of H-2Kd-
expressing targets (P815, L/Kd) following infection with
the rVV-ES-T499–507. However, H-2Kd-expressing tar-
gets (P815 or L/Kd; Table 4) were not lysed by the clone
19A8 when Tag determinants were supplied from infec-
tion by rVV-941T (Table 4; Fig. 4c). We note that nonspe-
cific lysis by CTL clone 19A8 approached 20% for se-
lected targets in those experiments (Table 4).
On the other hand, P815 cells (H-2d) infected with
rVV-941T were lysed efficiently by the Ld-restricted CTL
clone 1H7 (Table 4). In contrast to the Kd-restricted 19A8
clone, Tag-transformed H-2d cells such as mKSA and
BALB/c-pPVU0 were not efficiently lysed by clone 1H7
unless they were infected with rVV-941T (Table 4). CTL
clone 1H7 also failed to lyse B6/WT19 (H-2b) cells unless
those cells were infected with both the rVV-Ld and rVV-
TABLE 4
SV40 Tag-Specific H-2Kd- and H-2Ld-Restricted CTL Clones Distinguish between Presentation of T Antigen from Different Sources
Targetsa
Percentage specific lysis of targets by
Cells
Vaccinia
recombinant (rVV-)
19A8b 1H7
3:1 1:1 30:1 10:1
Experiment 1
mKSA None 64 59 1 0
(T1, H-2d)c 941T 70 64 57 54
ES-I (T206-215) 66 65 0 0
BALB/c-pPVU0 None 57 52 0 0
(T1, H-2d) 941T 59 52 33 38
ES-I 57 45 0 0
P815 941T 8 5 85 83
(T2, H-2d) ES-T499–507 70 59 6 2
ES-I 7 3 6 4
L/Kd 941T 20 7 0 0
(T2, H-2k 1 Kd) ES-T499–507 45 33 1 0
ES-I 17 6 0 0
T.1.1.1. 941T 18 8 46 31
(T2, H-2k 1 Ld) ES-I 19 7 3 2
Experiment 2
B6/WT-19 Kd 66 41 0 1
(T1, H-2b) Dd 22 10 0 0
Ld 18 9 1 1
ES-I 22 7 0 0
B6/WT-19 Kd 1 rVV-941Td 55 39 0 0
(T1, H-2b) Dd 1 rVV-941T 22 10 0 0
Ld 1 rVV-941T 16 6 36 30
ES-I 1 rVV-941T 23 11 0 0
a 51Cr-labeled cells were infected with the indicated rVVs at an m.o.i. of 10 for 6 h, washed, and mixed with the CTL clones for 5 h at the indicated
effector-to-target ratios.
b SV40 Tag-specific CTL clones. Clone 19A8 is H-2Kd-restricted; clone 1H7 is H-2Ld-restricted.
c T1, SV40 Tag-transformed cell line.
d 51Cr-labeled B6/WT-19 cells were infected with two rVVs at an m.o.i. of 10 each.
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941T recombinants (Table 4). The Tag-specificity of the
1H7 clone was indicated by the failure of that clone to
lyse targets infected with a control virus, rVV-ES-I (Table
4). The H-2Ld restriction of the 1H7 clone was indicated
by specific lysis of the rV V-941T-infected T.1.1.1. cells (H-2k
1 Ld) or B6/WT-19 cells (T1, H-2b) when infected with
both the rVV-941T and the rVV-Ld recombinants (Table 4).
Following prolonged time in culture, the SVCTL-A line,
like the clone 1H7, was unable to lyse Tag-transformed
H-2d cells under the conditions of a standard cytotoxicity
assay (data not shown).
Induction of T499–507-specific CTL in vivo
The immunogenicity of the H-2Kd-restricted T499–507
determinant was tested in BALB/c mice by immunization
with rVV-ES-T499–507. Three weeks after immunization,
splenocytes were restimulated in vitro with irradiated
mKSA cells and used as effectors in a 51Cr release assay
against SV40-transformed H-2d cells (BALB/c-pPVU0 and
mKSA) and P815 cells pulsed with the peptide LT499–507
or a control peptide. The results in Table 5 (Experiment 1)
show that splenocytes from mice immunized with rVV-
ES-T499–507 specifically lysed mKSA and BALB/c-
pPVU0 target cells (H-2d, T1), as well as P815 cells (H-2d,
T2), when pulsed with the target peptide LT499–507.
Consistent with results obtained using the H-2Kd-re-
stricted CTL clone 19A8 (Fig. 4, Table 4), the T499–507-
specific bulk-cultured CTL failed to specifically lyse P815
cells when infected with rVV-941T which directs expres-
sion of full-length Tag (data not shown).
The immunogenicity of the T499–507 epitope processed
from within T antigen was examined by immunizing
BALB/c mice with rVV-941T or SV40. The results in Table
5 (Experiment 2) indicate that immunization with rVV-
941T induced CTL which specifically lysed SV40 Tag-
transformed H-2d cells (mKSA and BALB/c-pPVU0). Un-
like the rVV-ES-T499–507-induced CTL, however, CTL
induced by immunization with rVV-941T did not recog-
nize P815 cells pulsed with the peptide LT499–507. Sim-
ilar results were obtained following immunization of
BALB/c mice with SV40 (Table 5, Experiment 3). Since
CTL specific for the T499–507 determinant were not in-
duced to detectable levels by immunization with full-
length Tag (SV40 or rVV-941T), the determinant T499–507
appears to be subdominant within full-length Tag.
T499–507-specific CTL induce rejection of transplanted
mKSA tumors
The ability of T499–507-specific CTL to induce rejection
of mKSA-induced tumors was tested in two ways. First,
the ability of CTL clone 19A8 to neutralize tumor induc-
tion by mKSA tumor cells in BALB/c mice was tested
using a tumor cell neutralization test used by us previ-
ously (Zarling and Tevethia, 1973a,b). Mice that received
a mixture of CTL clone 19A8 and mKSA tumor cells
remained tumor-free, while mice that received mKSA
tumor cells alone developed progressively growing tu-
mors (data not shown). The H-2Ld-restricted CTL clone
1H7, which failed to lyse mKSA in vitro (or other Tag-
transformed H-2d cells), also failed to neutralize mKSA
cells under similar conditions (data not shown).
To determine whether the H-2Kd-restricted CTL
TABLE 5
CTL Induction Following Immunization of BALB/c Mice with rV V-ES-T499–507, rV V-941T, or SV40
Effectorsa E:T
Percentage specific target cell lysis
mKSA BALB/c pPVU0
P815 1 peptideb
LT 499–507 LT 206–215
Experiment 1
rV V-ES-T499–507 50:1 78 49 74 3
(Bulk-culture CTL) 17:1 67 39 54 2
19A8 10:1 75 33 94 3
(CTL clone) 3:1 64 30 92 2
Experiment 2
rV V-941T 50:1 57 21 8 6
(Bulk-culture CTL) 17:1 42 16 3 3
Experiment 3
SV40 50:1 47 20 8 11
(Bulk-culture CTL) 17:1 22 10 3 4
19A8 6:1 48 47 59 8
(CTL clone) 2:1 45 40 61 4
a Bulk-culture CTL were generated by immunization of BALB/c mice with 1 3 107 PFU of rVV- (iv) or SV40 (sc) and restimulated in vitro with mKSA
cells. Effectors were assayed for lytic activity in a 5-h 51Cr release assay.
b P815 cells were radiolabeled and pulsed with the indicated peptide at a final concentration of 1 mM for 1 h before being washed and mixed with
effectors at the indicated effector-to-target ratios.
434 NEWMASTER ET AL.
epitope T499–507 could induce a tumor rejection re-
sponse in vivo, BALB/c mice were immunized with
rVV-ES-T499–507 (ES-linked minimal epitope), rVV-
941T (full-length Tag), or rVV-SC (no Tag insert). The
mice were challenged 3 weeks postimmunization with
1 3 105 mKSA tumor cells. All of the mice immunized
with the control recombinant rVV-SC developed pro-
gressively growing tumors and were sacrificed by 21
days postchallenge. By contrast, all of the mice immu-
nized with the rVV-941T were completely protected
from tumor formation (Fig. 5). Immunization with the
vaccinia recombinant encoding the H-2Kd-restricted
T499–507 determinant, rVV-ES-T499–507, conferred par-
tial protection in that 4 of 11 (Fig. 5A) or 5 of 8 (Fig. 5B)
animals remained tumor-free.
Our results demonstrate that CTL specific for a sub-
dominant H-2Kd-restricted CTL epitope corresponding to
Tag residues 499–507 induce rejection of transplantable
SV40 Tag-transformed tumor cells in vivo.
DISCUSSION
In this report, we have documented the induction of
SV40 Tag-specific CTL in BALB/c mice after immuniza-
tion with SV40, and in SV40-immunized mice that had
rejected a challenge of mKSA tumor cells. After in vitro
stimulation of spleen cells from the immunized mice with
gamma-irradiated mKSA cells, two Tag-specific CTL pop-
ulations (H-2Ld- and H-2Kd-restricted) were identified.
The H-2Ld-restricted CTL were predominant, as shown
by others (Schirmbeck et al., 1996); Tag-specific H-2Kd-
restricted CTL constituted a minor population which ex-
panded readily upon repeated in vitro stimulation with
irradiated mKSA cells. We have mapped the H-2Kd-re-
stricted epitope to Tag amino acids 499–507 (DYLDGS-
VKV). This epitope, when expressed as a minigene from
a recombinant vaccinia virus, is presented by H-2Kd
class I molecules to the Tag-specific CTL clones and is
immunogenic in vivo. Further, CTL clones specific for the
T499–507 epitope can neutralize the tumorigenicity of
mKSA cells in vivo. Immunization of BALB/c mice with the
rVV-ES-T499–507 provided partial protection against tu-
mor induction by mKSA cells. These results directly im-
plicate this H-2Kd-restricted T499–507 epitope in inducing
a tumor rejection response in the host. Whether T499–
507-specific CTL also participate in the rejection of
mKSA-induced tumors from mice which have been pre-
viously immunized with the full-length Tag (e.g., SV40 or
rVV-941T) remains unclear.
Our results indicate that the H-2Kd-restricted Tag
epitope DYLDGSVKV (T499–507) is a minor or subdominant
epitope. Immunization of BALB/c mice with full-length
Tag (Tag-transformed cells, SV40 or rVV-941T) did not
induce detectable levels of T499–507-specific CTL. Detec-
tion of T499–507-crossreactive CTL following immunization
with SV40 required several in vitro passages, while im-
munization of mice with the rVV-ES-T499–507 recombi-
nant induced a vigorous T499–507-specific CTL response.
These results imply that CTL targeted to the T499–507
determinant are available in the T cell repertoire, but that
this epitope may not be produced in sufficient quantities
from the full-length Tag to be immunogenic, or that other
factors may limit its immunogenicity from within Tag. In
this regard, the H-2Kd-restricted determinant T499–507
appears similar to the H-2Db-restricted Tag epitope V
(T489–497) which has been characterized as immunore-
cessive in H-2b mice (Tanaka et al., 1989; Tevethia, 1990;
Mylin et al., 1995a). In C57BL/6 (H-2b) mice, several
immunodominant CTL epitopes (Epitopes I, II/III, and IV)
have been identified within SV40 T antigen (reviewed in
Tevethia, 1990). Subsequent immunization of C57BL/6
mice with a cell line in which all of the immunodominant
epitopes were inactivated (by deletion or mutation) re-
vealed a novel, immunorecessive epitope (epitope V;
Tanaka et al., 1989; Deckhut et al., 1992; Mylin et al.,
1995a). Like the T499–507-specific CTL, epitope V-specific
CTL are efficiently induced following immunization of
H-2b mice with vaccinia recombinants which encode
epitope V minigenes (Fu et al., 1998). Nonetheless, while
CTL clones specific for the T489–497 (epitope V) or T499–507
determinants readily lyse Tag-transformed cells of the
FIG. 5. Immunization with vaccinia recombinants encoding full-
length SV40 Tag or an H-2Kd-restricted Tag CTL epitope, T499–507,
induces rejection of mKSA tumors. Groups of BALB/c mice were im-
munized iv with 1 3 107 PFU of the indicated vaccinia recombinants
and challenged 3 weeks later with 1 3 105 mKSA tumor cells. Mice
were scored as tumor bearing if palpable tumors (usually $3 mm) were
detected in the intrascapular region. (A) and (B) present results ob-
tained in two independent experiments.
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appropriate H-2 haplotype in vitro, it is difficult to dem-
onstrate CTL specific for either determinant following
immunization with full-length SV40 Tag (Tanaka et al.,
1989; Tevethia, 1990; Mylin et al., 1995a; Fu et al., 1998).
A number of subdominant or weak MHC class I-re-
stricted epitopes have now been described (Tanaka et
al., 1989; Chen et al., 1994; Feltkamp et al., 1995; Old-
stone et al., 1995; Johnston et al., 1996; Oukka et al., 1996;
van der Most et al., 1996; Vitiello et al., 1996; Deng et al.,
1997; Fu et al., 1997; Sparer et al., 1997; van der Most et
al., 1997). Nonimmunodominant epitopes have been
shown to contribute to protection in disease or tumor
challenge models. In the LCMV system, minor epitopes
were uncovered when dominant viral epitopes were in-
activated (Oldstone et al., 1995). Alternately, CTL re-
sponses to weak LCMV epitopes (identified within the
viral nucleoprotein by peptide motif searches) showed
enhanced immunogenicity under conditions where CTL
responses to the major epitopes were weakened [under
conditions of chronic infection (van der Most et al., 1996)]
or absent [by induction in a host deficient in the restrict-
ing element for the immunodominant CTL epitope (van
der Most et al., 1997)]. In the human papillomavirus
system, peptide immunization with nonimmunodominant
epitopes was shown to confer protection against lethal
tumor challenge (Feltkamp et al., 1995). Immunization
strategies targeted at nonimmunodominant epitopes of
influenza NP protein conferred partial protection against
lethal dose challenge (Oukka et al., 1996; Fu et al., 1997).
Adoptive transfer of a CTL clone specific for a subdomi-
nant H-2Db-restricted epitope presented by the EL-4 tu-
mor line caused rejection of previously implanted EL-4
tumors (Johnston et al., 1996). Results presented in this
study demonstrate that immunization of BALB/c mice
with rVV-ES-T499–507 provided protection against tu-
mors induced by transplantable SV40 Tag-transformed
mKSA cells. We are currently evaluating the ability of two
subdominant Tag epitopes, namely the H-2Db-restricted
epitope V (T489–497) and the H-2K
d-restricted determinant
T499–507, to induce tumor rejection in an SV40 Tag-trans-
genic tumor model.
An intriguing characteristic of the H-2Kd-restricted
T499–507 determinant is that CTL clones or bulk-culture
CTL specific for this epitope do not lyse H-2d cells (e.g.,
P815) infected with rVV-941T which directs synthesis of
full-length SV40 Tag. Infection of P815 cells with rVV-941T
does result in the synthesis of large amounts of Tag (data
not shown). We considered the possibility that the rVV-
941T sequence carries an alteration in the T499–507
epitope. This is unlikely because we have sequenced the
region of Tag encoding the CTL epitope and have found
it to be wild type. Alternatively, it is possible that ineffi-
cient liberation (from within Tag) or rapid destruction of
the T499–507 epitope limits recognition of rVV-941T-in-
fected cells. Further, enhanced proteolytic cleavage
within dominant or subdominant epitopes has been cor-
related with reduced immunological potency (Nieder-
mann et al., 1995; Yellen-Shaw et al., 1997). Recognition
of targets infected with rVV-ES-T499–507 may indicate
that either increased production of the epitope peptide or
bypassing TAP allows for efficient presentation of the
T499–507 determinant from a vaccinia recombinant. Per-
haps longer times are required to accumulate sufficient
amounts of the T499–507 peptide to trigger lysis by the
Tag-specific, H-2Kd-restricted CTL. Such accumulation
may be possible under conditions of sustained process-
ing of Tag epitopes which can occur in Tag-transformed
cells. Previous studies have documented that epitopes in
some heterologous viral proteins are not presented to
CTL in cells when expressed from vaccinia virus vectors
(Townsend et al., 1988).
Our results which show that the majority of the Tag-
specific CTL response in BALB/c mice is H-2Ld-re-
stricted agree with results recently reported by others
(Schirmbeck et al., 1996). Our study differs from that
reported by Schirmbeck et al. (1996) in that we can
generate both H-2Ld- and H-2Kd-restricted Tag-specific
CTL in BALB/c mice by immunization with SV40 (with or
without a subsequent mKSA challenge) while Schirm-
beck et al. (1996) could only generate Tag-specific CTL
by immunization with plasmid DNA and not with the
virus. The inability of Schirmbeck and co-workers to
generate Tag-specific CTL in BALB/c mice after SV40
infection may be related to a lower virus dose or the
route of immunization.
In an earlier study Pfizenmaier et al. (1978) reported
induction of H-2Dd-restricted SV40 Tag-specific CTL fol-
lowing immunization of BALB/c mice with SV40. Under
the conditions of our assays, we have been unable to
detect H-2Dd-restricted Tag-specific CTL. We did not
detect specific lysis by either bulk-culture CTL or the
SVCTL-A or SVCTL-B lines (derived following repeated in
vitro restimulation) of Tag-transformed cells infected with
a vaccinia recombinant which expressed the H-2Dd
class I molecule heavy-chain subunit (rVV-Dd) or of target
cells coinfected with the rVV-Dd and rVV-941T. It is pos-
sible, however, that a minor population of H-2Dd-re-
stricted Tag-specific CTL went undetected under the
conditions of our assays.
We report that H-2Ld-restricted bulk-culture CTL (ob-
tained following immunization with SV40 or rVV-941T)
recognized determinants presented on Tag-transformed
cells, or on H-2Ld-expressing cells infected with the
Tag-expressing vaccinia recombinant, rVV-941T. By com-
parison, the Tag-specific, H-2Ld-restricted CTL clones
failed to lyse Tag-transformed cells, but did recognize a
determinant(s) processed from full-length Tag when ex-
pressed from a recombinant vaccinia virus. The failure of
the H-2Ld-restricted CTL clones to lyse Tag-transformed
cells in standard cytotoxicity assays may indicate that
reduced amounts of the determinant(s) is processed
from Tag in transformed cells. It should be noted that the
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H-2Ld molecules expressed on mKSA cells are capable
of presenting antigen to the Tag-specific H-2Ld-restricted
CTL clones because these CTL clones are maintained in
vitro by stimulation with irradiated mKSA cells. Further-
more, mKSA and other Tag-transformed H-2d cells were
susceptible to lysis by the H-2Ld-restricted CTL clones
following infection with rV V-941T. This situation appears
analogous to the EBV system in which CTL clones main-
tained by in vitro stimulation with the EBV-transformed
LCL failed to lyse the same cells in standard cytotoxicity
assays (Hill et al., 1995). The EBV-transformed LCL did
become sensitive to lysis by the CTL clones after over-
expression of the appropriate EBV protein from a vac-
cinia recombinant (Hill et al., 1995).
The SV40 Tag-induced tumor system in BALB/c mice
is interesting in that the established tumor continues
to grow at the site of transplantation even though the
host becomes immune to tumor transplantation at a
distant site (reviewed in Tevethia, 1980). The tumor
cells are, however, efficiently rejected by mice preim-
munized with Tag (Zarling and Tevethia, 1973a). The
growth of the mKSA or other Tag-induced tumors of
H-2d origin in immunocompetent mice is not due to
downregulation of MHC class I expression as the
mKSA and the VLM cells continue to express H-2Kd,
H-2Dd, and H-2Ld class I antigens even after continu-
ous passage of these cells in immunocompetent mice.
This is in contrast to the downregulation of H-2b class
I antigens in SV40 Tag-transformed H-2b cells that are
adapted to grow in vivo in immunocompetent C57BL/6
mice (Flyer et al., 1983). In another study tumors de-
veloping in Tag transgenic H-2b mice were shown to
downregulate H-2b MHC class I antigens (Ye et al.,
1994). Furthermore, loss of antigenic determinants
from within Tag or loss of Tag expression can allow for
escape from immune surveillance in H-2b mice. Trans-
plantation of tumorigenic polyoma virus-transformed
cells which expressed SV40 Tag into SV40-immunized
H-2b mice lead to selective loss of SV40 Tag expres-
sion from the tumor cells (Flyer et al., 1983). Coculture
of H-2b cells transformed by SV40 Tag with Tag-spe-
cific CTL clones in vitro results in amino acid substi-
tutions and deletions in regions encoding the corre-
sponding CTL epitopes (Tanaka and Tevethia, 1988,
1990; Lill et al., 1992; Mylin et al., 1995b). How SV40-
transformed H-2d cells induce progressively growing
tumors without losing Tag expression or modulating
MHC class I antigen expression is not known (Kagi et
al., 1996).
MATERIALS AND METHODS
Mice, cell lines, and viruses
Male BALB/c mice were obtained from Jackson Labo-
ratories (Bar Harbor, ME) at 4–6 weeks of age, and were
routinely used before 12 weeks of age.
The cell lines used in this study are listed in Table 1a.
mKSA-ASC, henceforth designated as mKSA, and VLM
are SV40 T antigen-transformed cell lines of BALB/c
(H-2d) origin and are transplantable in immunocompetent
adult syngeneic mice (Kit et al., 1969; Drapkin et al., 1974;
Tevethia and McMillan, 1974). The BALB/c-pPVU0 cell
line was generated by transformation of primary BALB/c
kidney cells with the plasmid pPVU0 which contains
SV40 T antigen coding sequences (Kalderon and Smith,
1984). BALB/c cell lines which express derivatives of Tag
deleted of residues 499–507 or bearing a Y500A substi-
tution were derived by transfection using Tag-encoding
plasmid DNAs which were generated from the plasmid
pSelect-ESV-1 by site-directed mutagenesis as de-
scribed (Mylin et al., 1995a). P815 (H-2d) is a DBA/2-
derived mastocytoma (Dunn and Potter, 1957). B6/WT19
(H-2b) cells express wild-type SV40 Tag, and have been
described previously (Tevethia et al., 1979). T.1.1.1. was
derived from murine Ltk2 cells (H-2k) by transfection with
plasmids bearing the H-2Ld and the herpes simplex
thymidine kinase genes (Marguiles et al., 1983) and was
provided by Dr. Carol Reiss. The SV40-transformed, re-
combinant cell lines K5RSV (H-2Kb, H-2Dd, H-2Ld) and
KHTGSV (H-2Kd, H-2Db) were provided by Dr. Barbara
Knowles and have been described (Knowles et al., 1979).
L/Kd cells are L929 cells transfected with the neomycin
resistance gene and an H-2Kd gene which is controlled
by the SV40 early promoter (Eisenlohr et al., 1992), and
were provided by Dr. Jack Bennink (NIH).
Adherent cell lines were cultured in closed tissue
culture flasks in DMEM supplemented with 5% heat-
inactivated FBS (HyClone, Logan, Utah), 100 U of peni-
cillin per ml, 100 mg of streptomycin per ml, 2 mM
L-glutamine, 25 mg of kanamycin per ml, 20 mM HEPES,
and 0.15% (wt/vol) sodium bicarbonate. P815 cells were
maintained in RPMI 1640 medium (Gibco BRL, Gaithers-
burg, MD) supplemented with 10% heat-inactivated FBS,
2 mM L-glutamine, 5 3 1025 M b-mercaptoethanol, 25 mg
of pyruvic acid per ml, 100 U of penicillin per ml, 100 mg
of streptomycin per ml, and 5 mM HEPES (CTL medium).
SV40 (strain VA 45-54) was propagated in CV-1 cells, a
continuous monkey kidney cell line, as described (Te-
vethia et al., 1974a).
Recombinant vaccinia viruses
The recombinant vaccinia viruses used in this study
are listed in Table 1b. Recombinant vaccinia viruses
which express full-length SV40 Tag (rVV-941T) or an
H-2Db-restricted Tag CTL determinant (epitope I, T206–
215) fused to the ES derived from the adenovirus type 5
E3/19K glycoprotein (rVV-ES-I), as described elsewhere
(Fu et al., 1998). The control rVV-SC recombinant bears
no Tag insert and has been described (Fu et al., 1998).
Vaccinia virus recombinants which express MHC class I
heavy-chain subunits (H-2Kd, H-2Dd, H-2Ld) were gener-
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ously provided by Drs. Jack Bennink and Jonathan Yew-
dell (NIH; Restifo et al., 1993; Yewdell et al., 1993). A
recombinant vaccinia virus, encoding T antigen amino
acids 499–507 linked to the ES sequence was con-
structed according to the procedure described previ-
ously (Eisenlohr et al., 1992).
Tumor transplantation rejection test
BALB/c mice were immunized subcutaneously in the
intrascapular region at weekly intervals with 1.5 3 108
PFU of SV40 or intravenously with 1 3 107 PFU of vac-
cinia virus recombinant. Immunized and control mice
were challenged with 1 3 105 mKSA cells in the intra-
scapular region 2 to 3 weeks following the final immu-
nization. Mice were monitored for tumor development
three times a week.
Generation of bulk culture CTL for cytotoxicity assays
Bulk culture CTL were prepared from splenic lympho-
cytes obtained from BALB/c mice immunized with SV40,
mice immunized with SV40 which had resisted a chal-
lenge of mKSA tumor cells, or from mice immunized with
vaccinia virus recombinants according to procedures
described previously (Flyer et al., 1982; Tanaka et al.,
1988; Mylin et al., 1995a). Red cell-depleted splenic lym-
phocytes were cultured in 12-well plates (Costar, Cam-
bridge, MA). Each well was seeded with 1 3 107 spleno-
cytes and 5 3 105 gamma-irradiated (10,000 rad) mKSA
stimulator cells in 4 ml of CTL medium, incubated at
37°C in 5% CO2 for 6 days, and used as effectors in
51Cr
release assays.
Generation and maintenance of H-2d-restricted SV40
Tag-specific CTL lines and clones
To establish CTL lines, bulk-cultured CTL were sub-
cultured in vitro as described (Campbell et al., 1983;
Tanaka et al., 1988; Mylin et al., 1995b) in CTL medium
supplemented with gamma-irradiated mKSA stimulator
cells and either 7.5 U per ml of human recombinant IL-2
(a generous gift of Amgen, Thousand Oaks, CA) or 10%
(vol/vol) T-Stim culture supplement (Collaborative Bio-
medical Products, Bedford, MA) and 50 mM methyl-a-D-
mannopyranoside (Sigma Chemical Co., St. Louis, MO).
CTL clones were isolated by limiting dilution plating
(Tanaka et al., 1988) from CTL lines. Decreasing numbers
of bulk-cultured CTL were seeded into the wells of 96-
well U-bottom plates (Costar) with 1 3 105 gamma-
irradiated (2000 rad) naive splenocytes, 1 3 104 gamma-
irradiated (10,000 rad) mKSA stimulator cells, and either
7.5 U per ml of human recombinant IL-2 or 10% (vol/vol)
T-Stim culture supplement and 50 mM methyl-a-D-man-
nopyranoside. CTL clones were expanded from plates in
which fewer than 30% of the wells were scored positive
for growth.
CTL lines or clones were subcultured twice weekly in
CTL medium containing 7.5 U per ml of human recombi-
nant interleukin-2, or in 10% (vol/vol) T-Stim culture sup-
plement and 50 mM methyl-a-D-mannopyranoside. CTL
were provided with gamma-irradiated (10,000 rad) mKSA
or BALB/c-pPVU0 cells (1.67 3 105/ml of CTL medium) as
stimulators at each passage.
Tumor cell neutralization assay
Effector cells (Tag-specific CTL clones) were mixed
with mKSA tumor cells at an effector-to-target ratio of
10:1 and incubated at 37°C for 30 min in CTL medium
(lacking added IL-2) in a final volume of 1 ml. The mixture
was injected subcutaneously into naive BALB/c mice, as
described (Zarling and Tevethia, 1973a).
Preparation of target cells for use in cytotoxicity
assays
Procedures for preparation and use of peptides in
cytotoxicity assays have been described (Deckhut and
Tevethia, 1992; Mylin et al., 1995a). Peptides correspond-
ing to sequences within T antigen were synthesized in
the Macromolecular Core Facility of The Pennsylvania
State University College of Medicine by 9-fluoronyl-
methoxycarbonyl chemistry (9050 MilliGen PepSynthe-
sizer). Peptides were used for cytotoxicity assays without
further purification. 51Cr-labeled target cells were incu-
bated in CTL medium containing 1 mM synthetic peptide
for 1 h at 37°C in 5% CO2. Peptide-pulsed cells were
washed twice prior to use in the cytotoxicity assay. Tag
peptides are designated as ‘‘LT’’ followed by the numbers
of Tag residues which correspond to the first and last
residues of the synthetic peptide.
Cytotoxicity assay
Lysis of Tag-transformed, peptide-pulsed, or vaccinia
virus-infected target cells by BALB/c-derived, in vitro re-
stimulated splenic lymphocyte cultures or CTL clones
was measured by using a standard 51Cr release assay
as described (Deckhut and Tevethia, 1992; Mylin et al.,
1995a). Percentage of specific CTL-mediated 51Cr re-
lease was calculated by using the formula, % specific
release 5 [(E 2 S)/(M 2 S)] 3 100, where E indicates the
radioactivity released from targets incubated in the pres-
ence of effector cells, S indicates the spontaneous re-
lease of radioactivity by target cells incubated in the
presence of medium alone, and M indicates the quantity
of radioactivity released into the supernatant by target
cells incubated in the presence of 2.5% (wt/vol) SDS. All
determinations were made in triplicate.
Monoclonal antibodies and flow cytometric analysis
of cell surface molecules
Expression of MHC class I complexes on the surface
of SV40 Tag-transformed fibroblast cells or cells infected
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with recombinant vaccinia viruses was performed essen-
tially as described (Jennings et al., 1985) using the allele-
specific monoclonal antibodies SF1-1.1 (H-2Kd), 34-2-12
(H-2Dd), and 28-14-8 (H-2Ld/Db). Analysis of cell surface
markers on lymphocyte clones was performed as de-
scribed (Brehm et al., 1997) using monoclonal antibodies
53–6.7 (CD8), H57-597 (ab TCR), RM4-4 (CD4), and GL3
(gd TCR). Monoclonal antibodies were obtained from
PharMingen (San Diego, CA).
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